Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-Current Assets (2020 - 2025)

Insight Molecular Diagnostics' Non-Current Assets history spans 6 years, with the latest figure at $22.5 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 65.54% year-over-year to $22.5 million; the TTM value through Sep 2025 reached $176.4 million, down 31.97%, while the annual FY2024 figure was $6.3 million, 16.34% up from the prior year.
  • Non-Current Assets for Q3 2025 was $22.5 million at Insight Molecular Diagnostics, down from $23.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $127.4 million in Q2 2021 and bottomed at $5.4 million in Q4 2023.
  • The 5-year median for Non-Current Assets is $66.5 million (2021), against an average of $70.1 million.
  • The largest annual shift saw Non-Current Assets soared 183.02% in 2021 before it plummeted 92.71% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $120.4 million in 2021, then tumbled by 38.09% to $74.6 million in 2022, then tumbled by 92.71% to $5.4 million in 2023, then increased by 16.34% to $6.3 million in 2024, then skyrocketed by 256.55% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Non-Current Assets are $22.5 million (Q3 2025), $23.7 million (Q2 2025), and $7.2 million (Q1 2025).